Apr 3, 2020

Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alexandra O SokolovaHeather H Cheng

Abstract

PARP inhibitors (PARPi) are promising in BRCA2-altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12-altered tumors and promising results in PALB2-, RAD51B-, FANCA-, and BRIP1-altered tumors.See related article by Abida et al., p. xxx.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

RAD51B gene
CDK12 protein, human
PARP1
PALB2 gene
CHEK2 gene
Malignant Neoplasm of Prostate
Neoplasms
DNA Repair
Poly(ADP-ribose) Polymerase Inhibitors
Genes

Related Feeds

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.